The Experts below are selected from a list of 1440 Experts worldwide ranked by ideXlab platform
Amy S Paller - One of the best experts on this subject based on the ideXlab platform.
-
acral changes in Pediatric patients during covid 19 pandemic registry report from the covid 19 response task force of the society of Pediatric Dermatology spd and Pediatric Dermatology research alliance pedra
Pediatric Dermatology, 2021Co-Authors: Leslie Castelosoccio, Amy S Paller, Irene Laracorrales, Eric Bean, Sneha Rangu, Michelle Oboite, Carsten Flohr, Regina Celeste Ahmad, Valerie Calberg, Amy E GilliamAbstract:BACKGROUND/OBJECTIVE: In spring 2020, high numbers of children presented with acral pernio-like skin rashes, concurrent with the coronavirus disease 2019 (COVID-19) pandemic. Understanding their clinical characteristics/ infection status may provide prognostic information and facilitate decisions about management. METHODS: A Pediatric-specific Dermatology registry was created by the Pediatric Dermatology COVID-19 Response Task Force of the Society for Pediatric Dermatology (SPD) and Pediatric Dermatology Research Alliance (PeDRA) and was managed by Children's Hospital of Philadelphia using REDCap. RESULTS: Data from 378 children 0-18 years entered into the registry between April 13 and July 17, 2020 were analyzed. Data were drawn from a standardized questionnaire completed by clinicians which asked for demographics, description of acral lesions, symptoms before and after acral changes, COVID-19 positive contacts, treatment, duration of skin changes, laboratory testing including SARS-CoV-2 PCR and antibody testing, as well as histopathology. 229 (60.6%) were male with mean age of 13.0 years (± 3.6 years). Six (1.6%) tested positive for SARS-CoV-2. Pedal lesions (often with pruritus and/or pain) were present in 96%. 30% (114/378) had COVID-19 symptoms during the 30 days prior to presentation. Most (69%) had no other symptoms and an uneventful course with complete recovery. CONCLUSIONS AND RELEVANCE: Children with acral pernio-like changes were healthy and all recovered with no short-term sequelae. We believe these acral changes are not just a temporal epiphenomenon of shelter in place during the spring months of the first wave of the COVID-19 pandemic and may be a late phase reaction that needs further study.
-
biological agents in Pediatric Dermatology
2018Co-Authors: Emily B Lund, Amy S PallerAbstract:Biological agents are revolutionizing the treatment of immune-mediated disease across many disciplines, including rheumatology, gastroenterology, and Dermatology. For children with psoriasis, these medications represent a welcome alternative to broad immunosuppressants such as methotrexate and cyclosporine when topical therapies are inadequate. TNF inhibitors etanercept and adalimumab and the IL-12/23 inhibitor ustekinumab are currently approved in Europe for children ages 6 years and above, 4 years and above, and 12 years and above, respectively. In the US the FDA has approved etanercept (≥4 years) and Ustekinumab (≥12 years). Despite challenges associated with cost, experience, and safety, these promising new drugs are highly efficacious and well tolerated in Pediatric patients.
-
proceedings of the inaugural Pediatric Dermatology research alliance pedra conference
Journal of Investigative Dermatology, 2014Co-Authors: Dawn H Siegel, Joyce M C Teng, Keith A Choate, Beth A Drolet, Ilona J Frieden, Sheila Rittenberg, Wynnis L Tom, Mary L Williams, Lawrence F Eichenfield, Amy S PallerAbstract:Skin disease research involving children currently faces several major hurdles. As a result, many therapies are only available for off-label use in children, and many of the most pressing clinical needs of our Pediatric population remain unsolved. A strategic planning committee of the Society for Pediatric Dermatology (SPD) identified the need for an organized, inclusive research alliance to augment the resources of individual practitioners and preexisting smaller collaborative groups and facilitate robust, multicenter-based, translational and clinical research and therapeutic trials. A December 2011 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Roundtable on Pediatric Dermatology further detailed the therapeutic gaps and barriers to translation of scientific advances to clinical practice. Building on these forums, in July 2012, a group of interested investigators met in Monterey, CA, to develop the infrastructure for collaborative Pediatric skin research, now called the Pediatric Dermatology Research Alliance (PeDRA). The vision of PeDRA is to create sustainable collaborative research networks to better understand, prevent, treat, and cure dermatologic diseases in children. From that starting point, subcommittees and expert members were added, stakeholders were identified, and seed funding was garnered, with the first PeDRA stand-alone research meeting realized in Chicago, IL, in October 2013.
-
comprar hurwitz clinical Pediatric Dermatology 4th edition a textbook of skin disorders of childhood and adolescence expert consult online and print amy s paller 9781437704129 saunders
2011Co-Authors: Amy S PallerAbstract:Tienda online donde Comprar Hurwitz Clinical Pediatric Dermatology, 4th Edition A Textbook of Skin Disorders of Childhood and Adolescence (Expert Consult: Online and Print) al precio 145,95 € de Amy S. Paller, tienda de Libros de Medicina, Libros de Dermatologia y Venerologia - Dermatologia Pediatrica
-
impediments to research in Pediatric Dermatology the results of a survey of the members of the society for Pediatric Dermatology
Pediatric Dermatology, 2010Co-Authors: Jeffrey L Sugarman, Elena Pope, Amy S PallerAbstract:A research task force of the Society for Pediatric Dermatology (SPD) was established to investigate the barriers to expanding research in the field of Pediatric Dermatology. A survey was designed to address constraints limiting research activities among members of the SPD. A nine-question survey was distributed to SPD members at the annual meeting in 2007. Of the 70 respondents, 99% reported limitations to research activities. Of those, 90% (62/69) cited time constraints as a cause, 71% lack of funding, 38% lack of training, 35% lack of research infrastructure, 10% (7/69) lack of mentoring, and 25% (17/69) cited other reasons. SPD members face many challenges that curtail their bench and clinical research, although time constraints are most common. The high demand for clinic-directed activity and continuing workforce issues in the specialty likely contribute to the time constraints.
Lawrence F Eichenfield - One of the best experts on this subject based on the ideXlab platform.
-
clinical research in Pediatric Dermatology
2015Co-Authors: Lawrence F Eichenfield, Christine R TotriAbstract:Pediatric specific research in Dermatology is essential in order to provide evidence-based care for Pediatric patients. Yet, there are many unique considerations when conducting research with children as compared to their adult counterparts. The minimal risk standard, parental permission with child and adolescent assent, autonomy, and the label of a vulnerable population for Pediatric subjects are some of the important issues that must be considered. Despite these complexities, there are specific strategies that can be adopted in order to run a successful Pediatric Dermatology clinical research unit. In the last several years, federal legislation has been passed prioritizing Pediatric research, suggesting a promising future for researchers working with children and adolescents.
-
proceedings of the inaugural Pediatric Dermatology research alliance pedra conference
Journal of Investigative Dermatology, 2014Co-Authors: Dawn H Siegel, Joyce M C Teng, Keith A Choate, Beth A Drolet, Ilona J Frieden, Sheila Rittenberg, Wynnis L Tom, Mary L Williams, Lawrence F Eichenfield, Amy S PallerAbstract:Skin disease research involving children currently faces several major hurdles. As a result, many therapies are only available for off-label use in children, and many of the most pressing clinical needs of our Pediatric population remain unsolved. A strategic planning committee of the Society for Pediatric Dermatology (SPD) identified the need for an organized, inclusive research alliance to augment the resources of individual practitioners and preexisting smaller collaborative groups and facilitate robust, multicenter-based, translational and clinical research and therapeutic trials. A December 2011 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Roundtable on Pediatric Dermatology further detailed the therapeutic gaps and barriers to translation of scientific advances to clinical practice. Building on these forums, in July 2012, a group of interested investigators met in Monterey, CA, to develop the infrastructure for collaborative Pediatric skin research, now called the Pediatric Dermatology Research Alliance (PeDRA). The vision of PeDRA is to create sustainable collaborative research networks to better understand, prevent, treat, and cure dermatologic diseases in children. From that starting point, subcommittees and expert members were added, stakeholders were identified, and seed funding was garnered, with the first PeDRA stand-alone research meeting realized in Chicago, IL, in October 2013.
-
effective monitoring of isotretinoin safety in a Pediatric Dermatology population a novel patient symptom survey approach
Journal of The American Academy of Dermatology, 2011Co-Authors: Chelsea J Hodgkissharlow, Lawrence F Eichenfield, Magdalene A DohilAbstract:Background Assessment of adverse effects in Pediatric patients on oral isotretinoin has not been standardized and the exact incidence is unknown. Objective Our goal was to determine the usefulness of an isotretinoin symptom survey as a screening tool for assessment and quantification of adverse effects, including psychiatric symptoms, during isotretinoin treatment in a Pediatric population of different age groups. Methods We performed a retrospective chart review on a random sample of patients treated with isotretinoin at a tertiary Pediatric Dermatology clinic where patients completed an isotretinoin symptom survey at each visit. Responses were stratified by age group and psychiatric history. Results The charts of 102 patients, representing 123 courses of isotretinoin and 760 treatment-months, were reviewed. A total of 722 (95.0%) symptom surveys were complete and 38 (5.0%) were incomplete/missing. Recorded side effects were similar to published adult data; dry lips/dry skin were reported in 94.25% and 72.13% of treatment-months of isotretinoin, respectively. Psychiatric symptoms were reported in 1.65%, with no statistical difference between patients with or without a mental health history. Patients aged 11 to 15 years had similar side-effect profiles to those aged 16 to 21 years. Impaired night vision, nosebleeds, and dry/bloodshot eyes were more common in the older age group. Limitations This was a retrospective chart review, with known limitations. The study was performed at a tertiary referral center for Pediatric Dermatology, possibly allowing patient selection bias. Conclusions The isotretinoin symptom survey appears to be an effective screening tool to standardize monitoring of isotretinoin side effects in the Pediatric population.
-
the epidemiology of molluscum contagiosum in children
Journal of The American Academy of Dermatology, 2006Co-Authors: Magdalene A Dohil, Anne W Lucky, Amy S Paller, Lawrence F EichenfieldAbstract:Molluscum contagiosum (MC) is a viral disorder of the skin and mucous membranes characterized by discrete single or multiple, flesh-colored papules. Although MC as a clinical entity is well defined and commonly observed, few data regarding its epidemiology in the Pediatric population exist. Our purpose was to collect epidemiologic data on children with MC with regard to age, gender, ethnicity, degree of involvement, relation to pre-existing atopic dermatitis (AD), and immune status. A retrospective chart review was conducted. All subjects were seen at 3 tertiary Pediatric Dermatology referral centers with two of the sites based at a Children's Hospital. A total of 302 patient charts with the Current Procedural Terminology code diagnosis of MC seen over a 6- to 8-month period were reviewed. Approximately 80% of the patients were younger than 8 years old. The majority of patients (63%) had more than 15 lesions. All but one patient were otherwise healthy, as determined by history and clinical examination. Approximately 24% of the patients presented with a history of previous or active coexistent AD. However, children with AD were at risk for an increased number of lesions. These data provide valuable updated information on the demographics and clinical presentation of MC in Pediatric patients in the United States. Limitations include that this was a retrospective study with a population limited to tertiary Pediatric Dermatology referral centers.
Ilona J Frieden - One of the best experts on this subject based on the ideXlab platform.
-
proceedings of the inaugural Pediatric Dermatology research alliance pedra conference
Journal of Investigative Dermatology, 2014Co-Authors: Dawn H Siegel, Joyce M C Teng, Keith A Choate, Beth A Drolet, Ilona J Frieden, Sheila Rittenberg, Wynnis L Tom, Mary L Williams, Lawrence F Eichenfield, Amy S PallerAbstract:Skin disease research involving children currently faces several major hurdles. As a result, many therapies are only available for off-label use in children, and many of the most pressing clinical needs of our Pediatric population remain unsolved. A strategic planning committee of the Society for Pediatric Dermatology (SPD) identified the need for an organized, inclusive research alliance to augment the resources of individual practitioners and preexisting smaller collaborative groups and facilitate robust, multicenter-based, translational and clinical research and therapeutic trials. A December 2011 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Roundtable on Pediatric Dermatology further detailed the therapeutic gaps and barriers to translation of scientific advances to clinical practice. Building on these forums, in July 2012, a group of interested investigators met in Monterey, CA, to develop the infrastructure for collaborative Pediatric skin research, now called the Pediatric Dermatology Research Alliance (PeDRA). The vision of PeDRA is to create sustainable collaborative research networks to better understand, prevent, treat, and cure dermatologic diseases in children. From that starting point, subcommittees and expert members were added, stakeholders were identified, and seed funding was garnered, with the first PeDRA stand-alone research meeting realized in Chicago, IL, in October 2013.
-
Pediatric Dermatology inpatient consultations a retrospective study of 427 cases
Journal of The American Academy of Dermatology, 2013Co-Authors: Patrick Mcmahon, Deborah S Goddard, Ilona J FriedenAbstract:Background Limited reviews of inpatient Pediatric Dermatology (PD) exist in the current medical literature. Objective We sought to profile the inpatient PD consultations at a large tertiary care children's hospital. Methods We reviewed the electronic medical records of 427 consecutive PD consultations over a 52-month period from January 2006 to April 2010. The age, gender, diagnosis, requesting service, number of skin biopsies performed, and reason for admission to the hospital were recorded. Results Patients ranged in age from newborn to 17 years old: 18% were 6 weeks to 11 months of age. General Pediatrics was the service that most frequently consulted PD (44% of consultations). The most common diagnostic categories included infectious diseases, graft-versus-host disease, dermatitis, vascular anomalies, and drug eruptions. The most common diagnoses when hospitalization was primarily for skin-related disease were infections and vascular anomalies. Admission for skin disease associated with a systemic illness was most frequently for infections and drug eruptions. Limitations The retrospective nature of the study, its reliance on electronic medical records, and occurrence at a tertiary care children's hospital are potential limitations. Conclusions Information obtained from this study may be used to: (1) tailor teaching to relevant diagnoses for health care providers and trainees who care for children in a hospital setting, (2) inform clinicians about the array of conditions on which PD consultants provide input, and (3) understand the impact PD consultations have in a Pediatric tertiary care center.
Dawn H Siegel - One of the best experts on this subject based on the ideXlab platform.
-
diversity in Pediatric Dermatology a report from the Pediatric Dermatology research alliance and a call to action
Pediatric Dermatology, 2021Co-Authors: Olivia M T Davies, Jennifer T. Huang, Wingfield Rehmus, Latanya Benjamin, Deepti Gupta, Dawn H Siegel, Michael P SiegelAbstract:BACKGROUND/OBJECTIVES The Pediatric Dermatology Research Alliance (PeDRA) connects Pediatric dermatologists, trainees, basic scientists, allied health professionals, and patient advocates to improve the lives of children with skin disease through research. As a training pipeline for future Pediatric dermatologists and steward of research in the field, PeDRA has a responsibility to examine its history and take actionable steps to diversify its membership, grant recipients, study leads, research priorities, and leadership. METHODS In 2020, PeDRA formed an Equity, Diversity, and Inclusion Task Force to address this need. In an effort to assess PeDRA's past and plan for PeDRA's future, a review of PeDRA's membership, leadership, grant awardees, and research topics was conducted. RESULTS/CONCLUSIONS Results demonstrated gaps in PeDRA's current operational efforts to diversify the Pediatric Dermatology workforce and identified areas for improvement. Recommendations are proposed as a call to action for the community.
-
achieving equity and inclusion in Pediatric Dermatology research priorities and considerations
Pediatric Dermatology, 2021Co-Authors: Jennifer T. Huang, Olivia M T Davies, Dawn H SiegelAbstract:As we increase our focus and energy on equity, diversity, and inclusion (EDI)-relevant research, we must consider the "what, why, and how" of our work. The goals of this paper are to highlight unique issues Pediatric dermatologists face in providing equitable care, pose considerations when reporting data on race and ethnicity, and advocate for standardized classification of race and ethnicity in research.
-
proceedings of the inaugural Pediatric Dermatology research alliance pedra conference
Journal of Investigative Dermatology, 2014Co-Authors: Dawn H Siegel, Joyce M C Teng, Keith A Choate, Beth A Drolet, Ilona J Frieden, Sheila Rittenberg, Wynnis L Tom, Mary L Williams, Lawrence F Eichenfield, Amy S PallerAbstract:Skin disease research involving children currently faces several major hurdles. As a result, many therapies are only available for off-label use in children, and many of the most pressing clinical needs of our Pediatric population remain unsolved. A strategic planning committee of the Society for Pediatric Dermatology (SPD) identified the need for an organized, inclusive research alliance to augment the resources of individual practitioners and preexisting smaller collaborative groups and facilitate robust, multicenter-based, translational and clinical research and therapeutic trials. A December 2011 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Roundtable on Pediatric Dermatology further detailed the therapeutic gaps and barriers to translation of scientific advances to clinical practice. Building on these forums, in July 2012, a group of interested investigators met in Monterey, CA, to develop the infrastructure for collaborative Pediatric skin research, now called the Pediatric Dermatology Research Alliance (PeDRA). The vision of PeDRA is to create sustainable collaborative research networks to better understand, prevent, treat, and cure dermatologic diseases in children. From that starting point, subcommittees and expert members were added, stakeholders were identified, and seed funding was garnered, with the first PeDRA stand-alone research meeting realized in Chicago, IL, in October 2013.
Patrick Mcmahon - One of the best experts on this subject based on the ideXlab platform.
-
wait times health care touchpoints and nonattendance in an academic Pediatric Dermatology clinic
Pediatric Dermatology, 2019Co-Authors: Michael R Stephens, Patrick Mcmahon, Aditi S MurthyAbstract:BACKGROUND AND OBJECTIVES Timely access to Pediatric Dermatology care remains a challenge. While awaiting appointments, many patients and families utilize so-called health care touchpoints outside of the Dermatology clinic such as primary care or emergency department visits to address dermatologic concerns. Long waiting periods also factor into nonattendance rates at Pediatric Dermatology appointments. This observational retrospective study investigated wait times, relevant health care touchpoints, and factors related to nonattendance at a Pediatric Dermatology clinic. METHODS We reviewed demographic, health care touchpoint, and nonattendance data for patients referred by a primary care affiliate to the Children's Hospital of Philadelphia (CHOP) Pediatric Dermatology clinic from February 2016 to May 2017. Descriptive statistics were used to identify trends among analyzed variables. RESULTS We reviewed 250 patient records. The average number of touchpoints per patient was 0.56, and factors that significantly correlated with increased numbers of touchpoints included younger patient age and longer wait time while payer, primary diagnosis, and time of year were not associated. The nonattendance rate was 26%, and factors significantly associated with increased nonattendance rate included longer wait times and winter and spring appointments. CONCLUSION Long wait times impact numbers of touchpoints and appointment attendance rate when referring to Pediatric Dermatology. A platform such as teleDermatology may represent an opportunity to improve access to care by allowing for earlier input from the Pediatric dermatologist.
-
unilateral hypertrophy of the labia minora a case series
Pediatric Dermatology, 2018Co-Authors: Scarlett Boulos, Patrick Mcmahon, Marissa J Perman, Adam I. RubinAbstract:: Asymmetric hypertrophy of the labia minora is a variant of normal anatomy that has not been described in the Pediatric Dermatology literature. Although often asymptomatic, in some cases, it can cause functional, emotional, and psychological problems. We report the clinical characteristics and outcomes of four children who presented with unilateral labium minus hypertrophy. This case series aims to establish awareness of this condition among Pediatric dermatologists and provide recommendations regarding management.
-
Pediatric Dermatology inpatient consultations a retrospective study of 427 cases
Journal of The American Academy of Dermatology, 2013Co-Authors: Patrick Mcmahon, Deborah S Goddard, Ilona J FriedenAbstract:Background Limited reviews of inpatient Pediatric Dermatology (PD) exist in the current medical literature. Objective We sought to profile the inpatient PD consultations at a large tertiary care children's hospital. Methods We reviewed the electronic medical records of 427 consecutive PD consultations over a 52-month period from January 2006 to April 2010. The age, gender, diagnosis, requesting service, number of skin biopsies performed, and reason for admission to the hospital were recorded. Results Patients ranged in age from newborn to 17 years old: 18% were 6 weeks to 11 months of age. General Pediatrics was the service that most frequently consulted PD (44% of consultations). The most common diagnostic categories included infectious diseases, graft-versus-host disease, dermatitis, vascular anomalies, and drug eruptions. The most common diagnoses when hospitalization was primarily for skin-related disease were infections and vascular anomalies. Admission for skin disease associated with a systemic illness was most frequently for infections and drug eruptions. Limitations The retrospective nature of the study, its reliance on electronic medical records, and occurrence at a tertiary care children's hospital are potential limitations. Conclusions Information obtained from this study may be used to: (1) tailor teaching to relevant diagnoses for health care providers and trainees who care for children in a hospital setting, (2) inform clinicians about the array of conditions on which PD consultants provide input, and (3) understand the impact PD consultations have in a Pediatric tertiary care center.